1246264-45-8
1246264-45-8
Chemical Structure
Bezlotoxumab
Synonym(s): BLA761046; MBL-CDB1; MDX-1388
- CAS No.: 1246264-45-8
- Formula:N/A
- Molecular Weight:(145.54 kDa)
SMILES: [Bezlotoxumab]
Biological Activity: Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bezlotoxumab | 97.00% | Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zhang Z, et al. Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection. Infect Immun. 2015 Jan;83(1):405-16. [Content Brief]
- [2]. Navalkele BD, et, al. Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection. Biologics. 2018 Jan 18;12:11-21. [Content Brief]
- [3]. Johnson S, et al. Bezlotoxumab. Clin Infect Dis. 2019 Feb 1;68(4):699-704. [Content Brief]
Keywords
